NECLIFENSENectar Lifesciences Limited· PharmaceuticalsHighNegative
Announced Tue, 28 Apr · 13:20 IST

Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Court Stay ObtainedRegulatory & Legal View source PDF

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.8%1-day move
₹12.65
prior close
₹12.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4-0.8-0.4+0.9-0.8-1.6-3.7-4.1-2.6+13.7-3.8-1.3-7.8
Up moveDown movePending
AI summary

Nectar Lifesciences has provided an update on an Income Tax dispute that has now been fully resolved. The Deputy Commissioner of Income Tax, Chandigarh passed an order dated March 31, 2026 disposing of notices for Assessment Year 2017-18 in favor of the company. The case originated from notices under Sections 148 and 148A(b) of the Income Tax Act for AY 2017-18 to 2021-22. The company had challenged these notices in Punjab and Haryana High Court, which directed the IT Department to dispose of objections. Following rejections for AY 2018-19 to 2021-22 (where the company won via writ petitions), the final matter for AY 2017-18 has also been decided in the company's favor. The financial implication is NIL as the matter stands fully concluded. The company also acknowledged a delay in disclosure due to temporary inaccessibility of a former employee's email.

Likely market impact

Positive development for shareholders as all income tax disputes across AY 2017-18 to 2021-22 have been resolved in the company's favor with zero financial claims. This eliminates regulatory risk and uncertainty around the stock.